Navigation Links
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Date:6/1/2009

dels.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented, "Plans are underway to expand this study and evaluate additional patients with a variety of cancers as well as specifically those with colorectal and ovarian cancers. These additional data will guide our selection of the most promising solid tumor indications for further study in Phase 2. The recent initiation of Phase 1 studies in multiple myeloma and leukemia will allow us to extend the possible indications for ENMD-2076 into hematological malignancies where preclinical data have been encouraging. These data and the initiation of additional studies have added significant value to the program and, in line with the Company's strategy to accelerate the clinical development of ENMD-2076, partnering discussions continue."

To view a copy of the poster and slide presentations, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at www.entremed.com.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the Flt-3 and FGFR3, kinases which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angioge
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Initial Clinical Results for ENMD-2076
2. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
3. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
4. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
5. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
6. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
7. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. EntreMed to Present at The New York Society of Security Analysts Industry Conference
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 3, 2015  Cipla, a global pharmaceutical company which ... of all patients, today announced that its UK arm, ... two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals ... is valued at $550 million and will be an ... is over $200 million for the year ended Dec ...
(Date:9/3/2015)... Sept. 3,  2015 About Vision Care ... products considered for this report are Rx lenses, ... products are primarily used by consumer for vision ... Rx lenses and contact lenses require a prescription ... are cosmetic products that can be purchased like ...
(Date:9/3/2015)... 3, 2015 About dry eye syndrome Dry ... to deficient tear production or quick tear evaporation or ... types: aqueous tear deficient dry eye and evaporative dry ... do not produce enough tears, whereas meibomian gland dysfunction ... to slow tear evaporation and maintain tear stability. The ...
Breaking Medicine Technology:Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5Vision Care Market in the US 2015-2019 2Global Dry Eye Syndrome Market 2015-2019 2
... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) today ... Digestive Disease Week (DDW) conference highlighting additional analyses of ... investigational product for the treatment of Clostridium difficile ... The first analysis aimed to identify risk ...
... 2011 /PRNewswire-USNewswire/ – CoMeD – On Friday, May 6, ... an amendment to regulate vaccines containing mercury in Florida. ... sell, manufacture, deliver, import, administer or distribute any vaccine ... inorganic mercury per milliliter for children younger than age ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3
(Date:9/4/2015)... ... September 04, 2015 , ... On the ... effectively doubled the size of its annual health tech innovation program. Now featuring ... health startups to compete for cash and prizes to advance their technologies toward ...
(Date:9/4/2015)... ... 04, 2015 , ... The Providence Fertility Center will host a Fertility Cocktail ... egg freezing. , Date and Time: October 8, 2015 at Waterman Grille restaurant and ... informative event will discuss the basics of female fertility and egg freezing, and offer ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar ... (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply ... constantly evolving in the consumer goods industry, it can be difficult for companies ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... that CEREC technology is now available at CitiDent. CEREC is a newer method ... addition to saving time for patients by eliminating the need for multiple appointments, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a fresh ... its only mission and research focus: Water Life Science®. In the current warming ... evaporation is becoming dangerously accelerated. As a result of the global fresh water, ...
Breaking Medicine News(10 mins):Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3
... are invited to attend and cover the 2008 ... be held March 16-19, 2008, at the Hyatt ... organized by the Centers for Disease Control and ... Council of State and Territorial Epidemiologists, the Association ...
... It seems to plug calcium leaks that cause tiring ... News) -- An experimental drug may help fatigued athletes ... say physiologists at Columbia University Medical Center. , Tests ... regimens, tiny leaks of calcium continuously enter the muscle ...
... Johns Hopkins researchers from the Whiting School of Engineering and the ... on a chip - designed to mimic the chemical complexities of ... cells in the brain work together to form the nervous system. ... story in the February 2008 issue of the British journal Lab ...
... Tribune has published a,feature story on the terrible incidence ... loving dog owners, and treatments and scientific,research under way ... of release.,Morris Animal Foundation (MAF) is cited as leading ... 10 to 20 years. MAF can help provide the,press ...
... (WASHINGTON, February 12, 2008) A new study demonstrates for ... to create functional immune system blood cells, a finding which ... cells as an alternative source of cells for bone marrow ... and immune disorders, who need these transplants for treatment, was ...
... VEGAS, Feb. 12 For years, celebrities and,socialites ... products, including,toothpaste. Now, however, U.S. suburbanites and urban ... local drugstore to enjoy luxurious French oral,care., ... toothpaste in France for more than three,decades, has ...
Cached Medicine News:Health News:2008 International Conference on Emerging Infectious Diseases 2Health News:Muscle Fatigue Drug May Fight Heart Failure 2Health News:'Lab on a chip' mimics brain chemistry 2Health News:A functional immune system can be derived from embryonic stem cells, preliminary study finds 2Health News:A functional immune system can be derived from embryonic stem cells, preliminary study finds 3Health News:A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: